Overview
Neuraltus Pharmaceuticals is developing NP001, a novel immunomodulatory therapy targeting neuroinflammation in ALS patients by reprogramming inflammatory macrophages and microglia.
More in Neuropharmaceuticals
Latest industry news
Closed-Loop BCIs Charted as Next Frontier for Depression, Anxiety, and PTSD Treatment
2026-07-21 · Research
Instruments of Self-Knowledge: How Cognitive Assessment Tech Is Making the Invisible Mind Measurable
2026-07-21 · Industry
Top 10 Technologies Turning Self-Awareness Into Something You Can Actually See
2026-07-21 · Industry
China Clears Brain-Computer Interfaces for Commercial Use, Prompting Calls for Global Regulatory Alignment
2026-07-20 · Policy
Company details
Category
💊 Neuropharmaceuticals
Location
Palo Alto, CA, USA
Funding
Series B · $30M
Website
www.neuraltus.comListed
2026-06-15
Is this your company?
Claim this listing to add your logo, full description, team, and products. Premium listings get featured placement.
Claim & upgrade listingAdvertise
Reach neurotech professionals
Newsletter sponsorships, featured listings, and sponsored articles.
View packages →